Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1998 Jul;46(1):79-82.
doi: 10.1046/j.1365-2125.1998.00039.x.

Adverse effects of a single dose of (+)-sotalol in patients with mild stable asthma

G Devereux  1 , K Fishwick, T C Aiken, S J Bourke, D J Hendrick
Affiliations
Clinical Trial

Adverse effects of a single dose of (+)-sotalol in patients with mild stable asthma

G Devereux et al. Br J Clin Pharmacol. 1998 Jul.

Abstract

Aims: To investigate the effect of (+)-sotalol, which is not thought to possess clinically significant beta-adrenoceptor blocking activity, on airway responsiveness in subjects with mild asthma.

Methods: A placebo controlled, double-blind, single dose, cross over study, evaluating the effects of oral (+)-sotalol 300 mg and oral (+/-)-sotalol 240 mg, on airway responsiveness, FEV1, and heart rate in 18 asthmatic volunteers with quantifiable levels of airway responsiveness.

Results: Compared with placebo, (+)-sotalol induced a significant increase in airway responsiveness, and a significant decrease in FEV1, but there was no significant change in heart rate. Following (+/-)-sotalol there was no significant effect on airway responsiveness, but there were significant decreases in FEV1 and heart rate. In one subject both (+)-sotalol and (+/-)-sotalol provoked a 49% decrement in FEV1, and in another there were decrements of 20% and 18%, respectively.

Conclusions: Despite theoretical considerations, it cannot be assumed that (+)-sotalol is safe in patients with asthma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Airway responsiveness as expressed by PD20 to methacholine for placebo, (+)-sotalol, and (±)-sotalol in 16 subjects.
See this image and copyright information in PMC

References

    1. Antonaccio MJ, Gomoll AW. Pharmacologic basis for the anti-arrhythmic and haemodynamic effects of sotalol. Am J Cardiol. 1990;72(Suppl):27–37. - PubMed
    1. Funck-Brentano C, Silberstein DJ, Roden DM. A mechanism of d-(+) sotalol effects on heart rate not related to beta-adrenoreceptor antagonism. Br J Pharmacol. 1990;30:195–202. - PMC - PubMed
    1. Kato R, Ikeda N, Yabek R. Electrophysiologic effects of the levo-and dextro-rotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics. J Am Coll Cardiol. 1986;7:116–125. - PubMed
    1. Gomoll AW, Bartek MJ. Comparative beta-blocking activities and electrophysiologic actions of racemic sotalol and its optical isomers in anaethetised dogs. Eur J Pharmacol. 1986;132:123–135. - PubMed
    1. Levy JV, Richard V. Inotropic and chronotropic effects of a series of beta-adrenergic blocking drugs: some structure activity relationships. Proc Soc Exp Biol Med. 1966;122:373–385. - PubMed

Publication types